Search
News & Events
Childhood influenza vaccination rates improves with better accessMore children across Australia are being vaccinated against the flu since funding was expanded and access widened under the National Immunisation Program
Wrap up of the people, projects and updates from 2017 in the Vaccine Trials Group research area, and Dr Peter Richmond.
Contact us If you'd like to get in touch, please contact us by phone or email. Phone: 0400 450 240 Email: vtg@thekids.org.au Respiratory Syncytial
Meningococcal disease is caused by the bacteria Neisseria meningitidis, or 'meningococcus'. It's an uncommon but very serious disease that can result in death.
The Wesfarmers Centre is pleased to announce the successful recipients for the 2021 Round 2 Seed Funding Grants. Julie Hibbert | Validating a
Research
Nirsevimab immunisation of infants and respiratory syncytial virus (RSV)-associated hospitalisations, Western Australia, 2024: a population-based analysisChristopher Peter Hannah Blyth Richmond Moore MBBS (Hons) DCH FRACP FRCPA PhD MBBS MRCP(UK) FRACP OAM BSc (Hons) GradDipClinEpi PhD Centre Head,
Research
Designing a paediatric teleotology pilot in the UK: Outcomes from a scoping review of the literature, with insights from the Ear Portal pilot service in Perth, Western AustraliaTo inform the design of a United Kingdom (UK) paediatric teleotology pilot by analysing global teleotology initiatives and drawing on insights from a successful paediatric teleotology pilot service in Perth, Western Australia (Ear Portal).
Research
Hospitalizations Following Complex Hip Surgery in Children with Intellectual Disability: A Self-Controlled Case Series AnalysisTo evaluate the associations between complex hip surgery and subsequent hospitalizations in children with intellectual disability, including a subset of children with cerebral palsy.
Research
Assessing the Impact of Pneumococcal Conjugate Vaccine Immunization Schedule Change From 3+0 to 2+1 in Australian Children: A Retrospective Observational StudyIn mid-2018, the Australian childhood 13-valent pneumococcal conjugate vaccine schedule changed from 3+0 to 2+1, moving the third dose to 12 months of age, to address increasing breakthrough cases of invasive pneumococcal disease (IPD), predominantly in children aged >12 months. This study assessed the impact of this change using national IPD surveillance data.
Research
An Overview of the Skin Microbiome, the Potential for Pathogen Shift, and Dysbiosis in Common Skin PathologiesRecent interest in the diverse ecosystem of bacteria, fungi, parasites, and viruses that make up the skin microbiome has led to several studies investigating the microbiome in healthy skin and in a variety of dermatological conditions.